AMICUS THERAPEUTICS INC

Form 4

October 27, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

burden hours per

response...

OMB APPROVAL

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005 Estimated average

0.5

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person * Bloch Stephen M

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol

AMICUS THERAPEUTICS INC [FOLD]

(Check all applicable)

(Middle)

(Zip)

3. Date of Earliest Transaction (Month/Day/Year) 10/23/2008

_X__ Director 10% Owner Other (specify Officer (give title

C/O CANAAN PARTNERS, 285 **RIVERSIDE AVENUE, SUITE 250**

(State)

(First)

(Street) 4. If Amendment, Date Original

Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

WESTPORT, CT 06880

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

							• •	*	•
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or Code V Amount (D) Price			5. Amount of Securities Ownership Beneficially Form: Owned Direct (D) Following or Indirect Reported (I) Transaction(s) (Instr. 4) (Instr. 3 and 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	10/23/2008		S(1)	2,892	D	\$ 9.755 (2)	1,734,039	I	Canaan Equity III, L.P. (3)
Common Stock	10/23/2008		S <u>(4)</u>	108	D	\$ 9.755 (2)	64,751	I	Canaan Equity III Entrepreneurs, L.L.C. (5)
Common Stock	10/24/2008		S(1)	2,892	D	\$ 9.699 (6)	1,731,147	I	Canaan Equity III, L.P. (3)

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

Canaan Equity \$ Common $S^{(4)}$ 9.699 64,643 10/24/2008 108 D I Stock Entrepreneurs, L.L.C. (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of **SEC 1474** information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. iorNumber of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	.	ate	Amou Under Secur	tle and punt of erlying rities r. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	7 (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Relationships Reporting Owner Name / Address

> Director 10% Owner Officer Other

Bloch Stephen M C/O CANAAN PARTNERS 285 RIVERSIDE AVENUE, SUITE 250 WESTPORT, CT 06880

Signatures

/s/ John Lambrech, 10/27/2008 Attorney-in-Fact

**Signature of Reporting Person Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

X

Sales were made pursuant to a Rule 10b5-1 trading plan adopted by Canaan Equity III, L.P. on February 19, 2008, as amended on June 4, **(1)** 2008.

Reporting Owners 2

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

- This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line (2) range from \$9.70 to \$10.00. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
 - The reporting person is a member of Canaan Equity Partners III, L.L.C., which is the general partner of Canaan Equity III, L.P. Voting and investment power over these shares is exercised by the managers of Canaan Equity Partners III, L.L.C. in its role as general partner of
- (3) Canaan Equity III, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.
- (4) Sales were made pursuant to a Rule 10b5-1 trading plan adopted by Canaan Equity III Entrepreneurs, L.L.C. on February 19, 2008 as amended on June 4, 2008.
 - The reporting person is a member of Canaan Equity Partners III, L.L.C., which is the general partner of Canaan Equity III Entrepreneurs, L.L.C. Voting and investment power over these shares is exercised by the managers of Canaan Equity Partners III, L.L.C. in its role as a
- (5) general partner of Canann Equity III Entrepreneurs, L.L.C. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.
- This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line (6) range from \$9.50 to \$9.80. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.